Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I)
Annals of Surgical Oncology, 06/22/2012
Howard JH et al. – The findings suggest that over half of stage IV patients are candidates for resection and exhibit improved survival over patients receiving systemic medical therapy (SMT) alone, regardless of site and number of metastases. The authors have begun a multicenter randomized phase III trial comparing surgery versus SMT as initial treatment for resectable distant melanoma.
